NCT06613100 2025-12-01Evaluation of Neoadjuvant Xaluritamig in Localized Prostate CancerAmgenPhase 1 Recruiting40 enrolled
NCT06528210 2025-09-23Pembrolizumab With Androgen Deprivation Therapy and Radiotherapy for the Treatment of Patients With High Risk Localized Prostate CancerOHSU Knight Cancer InstitutePhase 2 Withdrawn